Authors

Latest:

Dr Liu on the Rationale for Targeting Wee1 in Ovarian Cancer

Joyce F. Liu, MD, MPH, discusses the role of Wee1 in cell cycle regulation and the rationale for targeting this protein in ovarian cancer.

Joyce O

Joyce O Shaughnessy, MD, Baylor-Sammons Cancer Center

Latest:

Dr. O'Shaughnessy on the Rationale for the MonarchE Trial in Breast Cancer

Joyce A. O'Shaughnessy, MD, discusses the rationale for the monarchE trial in breast cancer.

Joyce O Shaughnessy, MD, Baylor University Medical Center

Joyce Oâ€™Shaughnessy, MD, Texas Oncology

Joyce Ohm, PhD

Latest:

Epigenetic Studies May Unlock Clues to Gene Mutations

Researchers at Roswell Park Cancer Institute are formalizing their epigenetics program across dozens of disease research groups, with the goal of understanding what changes in the epigenome lead to cancer and identifying targeted, personalized ways to address these changes.

Joyce O'Shaughnessy, MD

Latest:

Preoperative Monitoring and Surgical Options for HER2+ Patients

Kandace P. McGuire, MD, provides clinical insights on how patient monitoring practices inform discussions around surgical options, providing the potential for deescalating surgical management.

Joyce OShaughnessy, MD, Baylor Charles A. Sammons Cancer Center

Joyce OShaughnessy, MD, Baylor University Medical Center

Joyce O'Shaughnessy, MD, Baylor University Medical Center Texas Oncology

Joyce O'Shaughnessy, MD, Baylor University Medical Center

Joyce O'Shaugnessy, MD, Baylor University Medical Center Texas Oncology

Joyce O'Shaugnessy, MD, Texas Oncology

Latest:

“HER2 Breast Cancer Talk”: A Review of Data from the SABCS 2020 Virtual Symposium

Joyce Vollmer

Latest:

The Importance of Correct Coding in Specialty-Focused Cancer Treatment Centers

When you consider how complex the system is, and how little training physicians get in medical school about coding, it stands to reason that practice leadership must emphasize its importance.

Ju Dong Yang, MD, MSc

Latest:

Dr. Yang on NASH-Associated HCC and Cirrhosis in Diagnosis of Liver Cancer

Ju Dong Yang, MD, MSc, discusses patients with nonalcoholic steatohepatitis (NASH)-associated hepatocellular carcinoma (HCC) who present without cirrhosis at the time of diagnosis of liver cancer.

Juan A. Reyna, MD

Latest:

Dr. Reyna on LUGPA Member Ancillary Services

Juan A. Reyna, MD, President, LUGPA, discusses in-office ancillary services among LUGPA members.

Juan Manuel O'Connor, MD

Latest:

Dr. O'Connor Discusses Rationale for CORRELATE Trial in mCRC

Juan Manuel O’Connor, MD, head, Department Gastrointestinal Oncology, Department of Clinical Oncology, Institute Alexander Fleming, Buenos Aires, discusses the rationale for the CORRELATE trial in metastatic colorectal cancer.

Juan P. Alderuccio, MD

Juan P. Alderuccio, MD, is an associate professor of medicine and clinical site disease group leader in the Lymphoma Section at Sylvester Comprehensive Cancer Center, University of Miami Health System.

Latest:

Dr Alderuccio on Loncastuximab Tesirine Plus Rituximab in High-Risk R/R Follicular Lymphoma

Juan P. Alderuccio, MD, discusses data from loxcastuximab tesirine plus rituximab in high-risk, relapsed/refractory follicular lymphoma.

Juanita Madison, MN, RN

Latest:

Juanita Madison on Handling the Provenge Process

Juanita Madison from the Seattle Cancer Care Alliance on Handling the Provenge Treatment Process

Jubilee Brown, MD

Latest:

Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer

Dr Brown discusses the rationale for the RAMP-301 trial of avutometinib plus defactinib in low-grade serous ovarian cancer.